Citations

Clear

16280 citation(s) found for "Yu, David".

Data Interoperability and Harmonization in Cardiovascular Genomic and Precision Medicine
Chahal, C. Anwar A. , Alahdab, Fares , Asatryan, Babken , Addison, Daniel , Aung, Nay , Chung, Mina K. , Denaxas, Spiros , Hall, Jennifer L. , Slotwiner, David J. , Vargas, Jose D. , Dunn, Jessilyn , Hall, Jennifer L , Pamir, Nathalie , Slotwiner, David J , Armoundas, Antonis A , Chahal, Choudhary Anwar A , Asatryan, Babken , Aung, Nay , Armoundas, Antonis A. , Alahdab, Fares

Mayo Clinic

Circulation: Genomic and Precision Medicine | May 9, 2025 | Volume: 18 | Issue: 3 | Pages: No page available

10.1161/circgen.124.004624 | PMID 40340425 Get It

Despite advances in cardiovascular care and improved outcomes, fragmented healthcare systems, nonequitable access to health care, and nonuniform and unbiased collection and access to healthcare data have exacerbated disparities in healthcare provision and further delayed the technological-enabled implementation of precision medicine. Precision medicine relies on a foundation of accurate and valid omics and phenomics that can be harnessed at scale from electronic health records. Big data approaches in noncardiovascular healthcare domains have helped improve efficiency and expedite the development of novel therapeutics; therefore, applying such an approach to cardiovascular precision medicine is an opportunity to further advance the field. Several endeavors, including the American Heart Association Precision Medicine platform and public-private partnerships (such as BigData@Heart in Europe), as well as cloud-based platforms, such as Terra used for the National Institutes of Health All of Us, are attempting to temporally and ontologically harmonize data. This state-of-the-art review summarizes best practices used in cardiovascular genomic and precision medicine and provides recommendations for systems’ requirements that could enhance and accelerate the integration of these platforms.
Epilepsy
Burkholder, David B. , Wirrell, Elaine

Mayo Clinic

Seminars in Neurology | May 8, 2025 | Volume: 45 | Issue: 02 | Pages: 178-179

10.1055/a-2556-8487 Get It

Aqueous Humor Dynamics Changes and Predictors of IOP Response to Latanoprost in Healthy Subjects
Kazemi, Arash , Reitinger, Jeremy C. , Gulati, Vikas , Fan, Shan , Sit, Arthur J. , Sit, Arthur J , Toris, Carol B. , Reed, David M. , Moroi, Sayoko E.

Mayo Clinic

Journal of Glaucoma | May 8, 2025 | Volume: 34 | Issue: 12 | Pages: 1056-1064

10.1097/ijg.0000000000002585 | PMID 40341017 Get It

Précis: In our study of the factors predictive of latanoprost response, we found that normotensive subjects with higher intraocular pressure, lower uveoscleral outflow, and higher body mass index had a greater response to 1-week treatment. Purpose: To evaluate relationships between variable intraocular pressure (IOP) responses to latanoprost and participant characteristics, baseline values and changes in aqueous humor dynamics (AHD) parameters. Methods: We assessed 226 eyes from 113 healthy participants. AHD parameters measured at baseline and after 1-week treatment with latanoprost included: IOP by pneumatonometry, episcleral venous pressure (EVP) by venomanometry, aqueous humor flow rate by fluorophotometry, outflow facility by 2-minute pneumatonography, and uveoscleral outflow calculated using the modified Goldmann equation. IOP responses were categorized into 4 groups: nonresponders (<10% reduction), all-responders (≥10% reduction), medium-responders (10%–20% reduction), and high-responders (≥20% reduction). Generalized estimating equation models were used to analyze treatment effects and compare groups. Results: Baseline IOP was higher in high-responders than medium-responders and nonresponders ( P =0.007 and P <0.001, respectively). Body mass index (BMI) was significantly higher in high-responders and all-responders compared with nonresponders ( P =0.02 and P =0.03, respectively). Responders had lower baseline uveoscleral outflow ( P =0.03). There were no significant differences in other baseline characteristics including EVP, outflow facility, and aqueous flow rate between the 4 groups. IOP decreased while outflow facility and uveoscleral outflow increased after latanoprost treatment in all responder groups but did not change in nonresponders. EVP and aqueous flow rate did not change significantly in any group. The change in uveoscleral outflow was greater in high-responders than in nonresponders ( P =0.004). Conclusions: In healthy subjects, higher baseline IOP, lower uveoscleral outflow and higher BMI are predictors of a greater IOP reduction by latanoprost. A greater increase in uveoscleral outflow is responsible for this larger response.
A Proposal for HPV-Associated Oropharyngeal Carcinoma in the Ninth Edition Clinical TNM Classification
Huang, Shao Hui, Su, Jie , Koyfman, Shlomo A. , Hoebers, Frank , Bahig, Houda , Yu, Eugene , Bartlett, Eric , Davis, Robin L. , Woody, N.M. , Nelson, Kristoff , Lavigne, Danny , Nguyen‐Tan, Phuc Félix, Létourneau‐Guillon, Laurent , Filion, Édith, Nagelschneider, Alex A. , Abel, Kathryn M. Van , Postma, Alida A. , Palm, Walter M. , Lydiatt, William M. , Patel, Snehal G. , Routman, David, Van Abel, Kathryn M , Huang, Shao Hui, Routman, David M. , Spreafico, Anna , Lee, Jonathan Wei Jie , Stock, Sarah Jane , Daniel, J. , Hoeben, Ann , Chua, Melvin L.K. , Xu, Wei , O'Sullivan, Brian P

Mayo Clinic

JAMA Otolaryngology–Head & Neck Surgery | May 8, 2025 | Volume: 151 | Issue: 7 | Pages: 655

10.1001/jamaoto.2025.0848 | PMID 40338536 Get It

Importance A subset of Union for International Cancer Control ( UICC )/ American Joint Committee on Cancer ( AJCC ) eighth edition TNM stage I and II human papillomavirus–positive oropharyngeal carcinoma has undesirable outcomes, which might have contributed to a lack of success in phase III deintensification trials. Refining clinical stage groups, especially in the overabundant cN1/stage I group, has become important for treatment selection. Objective To assess the prognostic importance of pretreatment lymph node (LN) characteristics to optimize case distribution and outcome homogeneity within the N classification system. Design, Setting, and Participants This is an international multi-institutional retrospective prognostic cohort study. Analysis of human papillomavirus–positive oropharyngeal carcinoma treated curatively from 4 institutions (International Collaboration of Oropharyngeal Cancer Network for N-Classification [ICON-N] dataset) provided a refined clinical staging proposal; an independent dataset (Centre Hospitalier de l’Université de Montréal [CHUM] dataset) validated the proposal. Neuroradiologists reviewed pretreatment computed tomography and/or magnetic resonance imaging for nodal features, including presence or absence of abnormal LN(s), retropharyngeal LN, laterality, number of abnormal LN, and imaging-detected extranodal extension (iENE). Data were collected from February to May 2023, and data were analyzed from June to July 2023. Exposures Definitive chemoradiotherapy/radiotherapy or definitive surgery with or without postoperative chemoradiotherapy/radiotherapy. Main Outcomes and Measures The primary end point was overall survival. A Cox proportional hazards multivariable model was used to estimate adjusted hazard ratios (AHRs) and to derive an optimal clinical TNM stage classification (AHR-stage schema) incorporating the strongest prognostic nodal features within the UICC/AJCC eighth edition TNM framework after confirming the prognostication of iENE status. The performance (according to overall normalized scores and ranking) of the AHR-stage schema against the current UICC/AJCC eighth edition TNM staging system was evaluated for hazard consistency, hazard discrimination, prognostic importance, and sample size balance. Validation was performed in the CHUM dataset. Results The ICON-N dataset comprised 2053 patients, including 1898 (92.5%) with cN-positive disease and 155 (7.5%) with cN0 disease; a total of 298 (14.5%) were female, and the mean (SD) age was 60.6 (9.3) years. iENE-positive disease was identified in 710 of 1898 patients with cN-positive disease (37.4%). The median (range) follow-up was 5.1 (0.1-14.7) years. iENE was the strongest prognostic nodal feature in multivariable analysis; the AHR for iENE-positive vs iENE-positive disease was 2.43 (95% CI, 1.96-3.03) in the ICON-N dataset and 2.04 (95% CI, 1.28-3.23) in the CHUM dataset (n = 451). Reclassifying iENE-positive cases 1 stratum higher for N categorization without altering iENE-negative cases yielded an AHR-stage schema that outperformed the current TNM staging system in disease-free and overall survival with a lower (ie, better) overall normalized score (2 vs 3). Conclusions and Relevance In this study, reclassifying each N category 1 stratum higher for iENE-positive disease resulted in better disease-free and overall survival. The proposed new classification outperformed the currently TNM staging system in risk stratification and may facilitate future clinical trial design, outcomes research, and patient care.
Gastric Cancer, Version 2.2025, NCCN Clinical Practice Guidelines In Oncology
Ajani, Jaffer A. , D’Amico, Thomas A., Bentrem, David J., Corvera, Carlos U. , Das, Prajnan , Enzinger, Peter C. , Enzler, Thomas , Gerdes, Hans, Grierson, Patrick , Hofstetter, Wayne L. , Ilson, David H. , Jalal, Shadia I. , Kleinberg, Lawrence , Lacy, Jill , Lee, Byrne , Licciardi, Frank, Ly, Quan P. , Matsukuma, Karen , McNamara, Michael, Mukherjee, Sarbajit , Mulcahy, Mary F. , Reddi, Deepti , Reznik, Scott I. , Roses, Robert E. , Strong, Vivian E. , Su, Stacey, Uboha, Nataliya V. , Willett, Christopher G. , Yoon, Harry H. , McMillian, Nicole R., Stein, MaryElizabeth , Gupta, Garima , Ajani, Jaffer A , Bentrem, David J. , Gibson, Michael K. , Gupta, Garima , Kim, Sunnie S. Y. , Klempner, Samuel J. , Lloyd, Shane , Merkow, Ryan P. , Perry, Kyle A. , Pimiento, José M. , Reddi, Deepti , Wainberg, Zev A. , Woo, Yanghee

Mayo Clinic

Journal of the National Comprehensive Cancer Network | May 8, 2025 | Volume: 23 | Issue: 5 | Pages: 169-191

10.6004/jnccn.2025.0022 | PMID 40341199 Get It

Gastric cancer is the fifth leading cause of cancer-related deaths worldwide. Over 95% of gastric cancers are adenocarcinomas, which are typically classified based on anatomic location and histologic type. Gastric cancer generally carries a poor prognosis because it is often diagnosed at an advanced stage. Systemic therapy can provide palliation, improve survival, and enhance the quality of life in patients with locally advanced or metastatic disease. The implementation of biomarker testing has had a significant impact on clinical practice and patient care. Targeted therapies have demonstrated encouraging results in clinical trials for the treatment of patients with locally advanced or metastatic disease. This selection from the NCCN Clinical Practice Guidelines in Oncology for Gastric Cancer highlights recommendations for biomarker testing and discusses updates for the treatment of advanced disease, including peritoneal carcinoma as only disease and unresectable locally advanced, recurrent, or metastatic disease.
EULAR /American College of Rheumatology Classification Criteria for Pediatric Chronic Nonbacterial Osteomyelitis
Zhao, Yongdong , Oliver, Melissa , Schnabel, Anja , Wang, Zhaoyi , Marino, Achille , Aguiar, Cassyanne L. , Akikusa, Jonathan , Akça, Ümmüşen Kaya , Almeida, Beverley, Appenzeller, Simone , Balay‐Dustrude, Erin , Bilginer, Yelda , Cabral, David A. , Capponi, Martina , Donaldson, Nathan , Egeli, Buğra Han , Iyer, Ramesh S. , Jansson, Annette, Kostik, Inna , Kostik, Mikhail M. , Kovalick, Leonard K., Kozu, Kátia Tomie , Lee, Tzielan , Mahmood, Kamran , Muse, Ian, Mushkin, Alexander, Nowicki, Katherine D. , Nuruzzaman, Farzana , Pham, Trang Sophia, Potts, Lauren, Ramanan, Athimalaipet V., Rogers, Nathan D. , Grim, Andrew W. , Romano, Micol , Rosenwasser, Natalie , Sato, T. Shawn , Soep, Jennifer B. , Stern, Sara , Strauß, Timmy , Taneja, A. , Theos, Alexander C. , Tucker, Lori B. , Vogel, Lisa, Yasin, Shima , Wong, Stephen C. , Bouchalová, Kateřina , Hendry, Alison M., Cain, Kevin C. , Girschick, Hermann , Hedrich, Christian M. , Laxer, Ronald M. , Ferguson, Polly J. , Naden, Raymond P., Özen, Seza , Oliver, Melissa S , Akca, Ummusen Kaya , Appenzeller, Simone , Balay-Dustrude, Erin , Basiaga, Matthew L. , Kostik, Mikhail , Lapidus, Sivia K , Marrani, Edoardo , Mosa, Doaa Mosad , Nowicki, Katherine D , Pardeo, Manuela , Potts, Lauren , Ravelli, Angelo , Tucker, Lori B , Dedeoglu, Fatma , Hedrich, Christian M , Ozen, Seza , Wu, Eveline Y. , Başaran, Özge , Fox, Emily J., Insalaco, Antonella , Lapidus, Sivia , Lenert, Aleksander , Mahmood, Kamran, Mushkin, Alexander, Onel, Karen , Pham, Trang Sophia, Ramanan, Athimalaipet Vaidyanathan , Simonini, Gabriele , Dedeoğlu, Fatma

Mayo Clinic

Arthritis & Rheumatology | May 8, 2025 | Volume: 78 | Issue: 3 | Pages: 537-547

10.1002/art.43137 | PMID 40342207 Get It

Objective To develop and validate classification criteria for pediatric chronic nonbacterial osteomyelitis (CNO) jointly supported by EULAR and the American College of Rheumatology (ACR). Methods This international initiative had 4 phases: (1) candidate items were proposed in a survey of pediatric rheumatologists, (2) criteria definition and reduction by Delphi and nominal group technique exercises, (3) criteria weighting using multicriteria decision analysis, and (4) refinement of weights and threshold score in a development cohort of 441 patients and validation in another cohort of 514 patients. Results The new EULAR/ACR classification criteria for CNO require typical radiographic or magnetic resonance imaging findings and bone pain as an obligatory entry criterion and exclusion criteria of malignancy, infection, vitamin C deficiency, and hypophosphatasia, followed by additive weighted criteria in 5 clinical (site of bone lesions, pattern of bone lesions, age at onset, coexisting conditions, fever) and 4 pathology/laboratory domains (bone biopsy findings if done, anemia, C‐reactive protein level, and erythrocyte sedimentation rate). A total score ≥55 is required for classification as CNO. The new criteria had a sensitivity of 82% and specificity of 98% in the validation cohort. Conclusion These new classification criteria for pediatric CNO developed with international input reflect current views about CNO, have high specificity and good sensitivity, and provide a key foundation for future CNO research.
Clinical Outcome and Molecular Profile in Patients with DDX41 Mutation Hot-Spots
Toumeh, Nadia , Jabban, Yazan, Nanaa, Ahmad , He, Rong , Viswanatha, David S., Foran, James M. , Yi, Cecilia Y. Arana , Saliba, Antoine N. , Shah, Meera , Mangaonkar, Abhishek A. , Patnaik, Mrinal M. , Alkhateeb, Hassan B. , Al‐Kali, Aref , Saliba, Antoine N. , Viswanatha, David, Arana Yi, Cecilia Y , Saliba, Antoine N , Hefazi Torghabeh, Mehrdad, Hogan, William J , Shah, Mithun V , Alkhateeb, Hassan B , Al-Kali, Aref , Saliba, Antoine N , Jevremović, Dragan , Yi, Cecilia Arana , Hefazi, Mehrdad , Hogan, William J.

Mayo Clinic

Hematology Reports | May 8, 2025 | Volume: 17 | Issue: 3 | Pages: 26

10.3390/hematolrep17030026 | PMID 40407636 Get It

Background/Objectives: DDX41, DEAD-box RNA helicase 41 gene located on chromosome 5q25.3, is one of the most mutated genes in patients with germline predisposition to myeloid neoplasms. Germline and somatic mutations often have different locations and patterns of mutation, with some hotspots displaying diversity based on ethnicity. We aimed to explore clinical outcomes in patients with various DDX41 hot-spot mutations. Methods: This was a retrospective study of patients at Mayo Clinic with DDX41 mutation identified through Next Generation Sequencing (NGS) between 2018 and 2024. We completed unadjusted comparisons using continuous or categorical variables, and survival rates were assessed using the Kaplan–Meier method and cox regression analysis. Results: Overall survival appears to be higher in those with p.M1| when compared to p.Asp140GlyFs*2 and p.Arg525His, with comparable survival between p.Arg525His and p.Asp140GlyFs*2. Among males with p.M1| who underwent bone marrow transplant, those who underwent bone marrow transplant appeared to have lower survival rates, although not statistically significant. Our study was limited by a small sample size, therefore limiting our ability to reach significance. Conclusions: Our findings suggest potential implications for clinical outcomes based on DDX41 mutation hot-spots.
Prevalence of Hypercortisolism in Difficult-to-Control Type 2 Diabetes
Buse, John B. , Kahn, Steven E. , Aroda, Vanita R. , Auchus, Richard J. , Busch, Robert S. , Christofides, Elena A. , DeFronzo, Ralph A. , Eilerman, Bradley , Findling, James W. , Handelsman, Yehuda , Miller, Harold J., Ownby, Jonathan G., Parker, John C. , Philis‐Tsimikas, Athena , Rosenstock, Julio , Shanik, Michael H., Sloan, Lance L., Tudor, Iulia Cristina , Schlafly, Tina K. , Einhorn, Daniel , Investigators*, CATALYST, Kruszon, Lauren, Fruiterman, Abbey, Handelsman, Yehuda, Heidarpour, Narges, Ownby, Jonathan G., Stephens, Nashia, Aroda, Vanita R., Gyurko, Rita, Rao, Pratibha, Paulus, Kelly, Kipnes, Mark, Ryan, Terri, Shanik, Michael H., Iannuzzi, Lisa, Umpierrez, Guillermo, Centeno, Gloria, Eskeland, Andrew, Swerdloff, Ronald S., Ruiz, Elizabeth, Park, Jean, Hurtado, Maria, Ghazi, Adline , Hamm, M., Ducote, Rosina, Blonde, Lawrence , Williams, Shannon, Wyne, Kathleen , Aldrich, Lindsey, Ahmann, Andrew , Branigan, Deborah , Nakhle, Samer, Sandry, Sasha, Rosal, Rosario, Hardy, Cashmere, Sloan, Lance , Sloan, Kátia Portero , Lerman, Sam, Simmons, Mary, Auchus, Richard J., Varela, Tamara Blanco, Gassaway, Franziska, DeFronzo, Ralph A., Puckett, Curtiss, Atkinson, Karen, Zimmerman, Michael, Jacobsen, Colleen, Wenker, Matthew, Schultz, Austin, Lender, Dan, Camacho, Allison, Leibowitz, Mark D., Sánchez, Rosario, Delgado, John , Jaasko, Kari, Hsia, Stanley H. , Rodríguez, Cecilia, Guzman, David , Garibay, Lourdes, Chang, Margaret, Nixon, Tatyana, Christofides, Elena A , DeFronzo, Ralph A , Eilerman, Bradley , Fonseca, Vivian , Handelsman, Yehuda , Rosenstock, Julio , Umpierrez, Guillermo E. , Schlafly, Tina K , Philis-Tsimikas, Athena , Kahn, Steven , Buse, John B , Bailey, Timothy S. , Bancos, Irina , Fonseca, Vivian , Hamidi, Oksana , Pratley, Richard E. , Sloan, Lance L., Investigators*, CATALYST, Handelsman, Yehuda, Ownby, Jonathan G., Aroda, Vanita R., Shanik, Michael H., Umpierrez, Guillermo, Centeno, Gloria, Ruiz, Elizabeth, Aldrich, Lindsey, Botte, Jennifer, Hardy, Cashmere, Martin, Maria Jesus , Lovre, Dragana , Simmons, Mary, Auchus, Richard J., Pop‐Busui, Rodica , DeFronzo, Ralph A., Zimmerman, Michael, Wenker, Matthew, Schultz, Austin, Chang, Margaret, Nixon, Tatyana

Mayo Clinic

Diabetes Care | May 7, 2025 | Volume: 48 | Issue: 12 | Pages: 2012-2020

10.2337/dc24-2841 | PMID 40249765 Get It

OBJECTIVE Despite the use of multiple glucose-lowering medications, glycemic targets are not met in a significant fraction of people with type 2 diabetes. In this prospective, observational study we assessed the prevalence of hypercortisolism, a potential contributing factor to inadequate glucose control. RESEARCH DESIGN AND METHODS Individuals with type 2 diabetes and HbA1c 7.5%–11.5% (58–102 mmol/mol) on two or more glucose-lowering medications with or without micro-/macrovascular complications or taking multiple blood pressure–lowering medications were screened with a 1-mg dexamethasone suppression test. Common causes of false-positive DSTs were excluded. The primary end point was the prevalence of hypercortisolism, defined as post-DST cortisol &gt;1.8 μg/dL (50 nmol/L). Characteristics associated with hypercortisolism were assessed with multiple logistic regression. The percentage and characteristics of participants with hypercortisolism and adrenal imaging abnormalities were also assessed. RESULTS Post-DST cortisol was unsuppressed in 252 of 1,057 participants (prevalence 23.8%; 95% CI 21.3, 26.5). Hypercortisolism prevalence was 33.3% among participants with cardiac disorders and 36.6% among those taking three or more blood pressure–lowering medications. Adrenal imaging abnormalities were reported in 34.7% of participants with hypercortisolism. Use of sodium–glucose cotransporter 2 inhibitors (odds ratio 1.558), maximum-dose glucagon-like peptide 1 receptor agonists (1.544), tirzepatide (1.981), or a higher number of blood pressure–lowering medications (1.390); older age (1.316); BMI &lt;30 kg/m2 (1.639); non-Latino/Hispanic ethnicity (3.718); and use of fibrates (2.676) or analgesics (1.457) were associated with higher prevalence (all P &lt; 0.03). CONCLUSIONS Hypercortisolism was associated with hyperglycemia in approximately one-quarter of individuals with inadequately controlled type 2 diabetes despite multiple medications.
Breast Tumor-Bed Biopsy for Pathological Complete Response Prediction
Cecchini, Reena S. , Santos, Jennifer De Los , Umphrey, Heidi , Julian, Thomas B. , Mamounas, Eleftherios P. , White, Julia , Balanoff, Christa , Tan, Antoinette R. , Weber, Joseph J., Edmonson, David , Brown‐Glaberman, Ursa, Diego, Emilia J. , Teshome, Mediget , Matsen, Cindy , Seaward, Samantha A. , Wapnir, Irene , Wagner, Jamie L., Tjoe, Judy A., Thompson, Alastair M., Seaward, Samantha A , Basik, Mark , Mamounas, Eleftherios P. , Lucas, Peter C. , Wolmark, Norman

Mayo Clinic

JAMA Surgery | May 7, 2025 | Volume: 160 | Issue: 7 | Pages: 723

10.1001/jamasurg.2025.1072 | PMID 40332918 Get It

Importance Use of modern neoadjuvant chemotherapy (NAC) regimens has markedly increased rates of pathologic complete response (pCR) in breast cancer, raising the question of whether surgical removal of the primary tumor is required for patients with pCR. For surgery to be omitted, one must be able to accurately predict pCR before surgery. Objective To investigate if adding post-NAC core needle biopsy of the tumor bed to trimodality imaging in patients who have clinical complete response (cCR) will predict pCR (resolution of both invasive disease and ductal carcinoma in situ) in 90% or more cases. Design, Setting, and Participants This was a phase 2, prospective, nonrandomized clinical trial. Patients were enrolled from August 2017 to June 2019. This is the final analysis, which was completed in December 2023. The setting included academic and community hospital center members of NRG (ie, the National Surgical Adjuvant Breast and Bowel Project, the Radiation Therapy Oncology Group, and the Gynecologic Oncology Group) in the US and Canada. Patients with operable (T1-T3, stage I-III) invasive ductal carcinoma who completed NAC and achieved cCR and radiological complete response (rCR) or near rCR by mammography (mass ≤1 cm and no malignant microcalcifications), ultrasound (mass ≤2 cm), and magnetic resonance imaging (no mass with rapid rise or washout kinetics). Interventions Patients underwent marker-directed stereotactic multiple-core needle biopsy of the tumor bed with marker placement before breast-conservation surgery. Main Outcomes and Measures End points were negative predictive value (NPV) and sensitivity of the biopsy. Results A total of 105 patients were enrolled with 101 evaluable (mean [SD] age, 52.8 [10.5] years); 77 patients (76.2%) were younger than 60 years, and all breast cancer subtypes were represented with 32 (31.7%) triple-negative breast cancer, 21 (20.8%) hormone receptor–positive/epidermal growth factor receptor 2 ( ERBB2 ; formerly HER2 )–negative ( ERBB2 −) breast cancer, and 46 (45.5%) ERBB2 -positive ( ERBB2 +) breast cancer. In 101 evaluable patients, 36 had residual disease at surgery (pCR = 64%). With imaging criteria, NPV of the biopsy was 78.3% (95% CI, 67.9%-86.6%), and the sensitivity of the biopsy was 50% (95% CI, 32.9%-67.1%). In an exploratory subset analysis, the NPV in patients with ERBB2 + breast cancer was 90% (95% CI, 76.3%-97.2%). On retrospective central review, 62 of 101 enrolled patients met imaging eligibility criteria. In this exploratory post hoc analysis, NPV in these patients was 86.8% (95% CI, 74.7%-94.5%). Conclusions and Relevance These findings do not support breast conservation treatment without surgery based on the study criteria for cCR and rCR/near rCR by trimodality imaging and negative tumor-bed biopsy. Strict adherence to imaging criteria may be required to achieve acceptable predictive values. TRIAL Registration ClinicalTrials.gov Identifier: NCT03188393
Long‐Term Outcomes of Fenofibrate for Treatment of Ischemic Cholangiopathy in Donation After Circulatory Death Liver Transplantation
Jayasekera, Channa R. , Barnhill, Michele , Chascsa, David M. , Croome, Kristopher P. , Carey, Elizabeth J. , Vargas, Hugo E. , Chascsa, David M , Croome, Kris P , Vargas, Hugo E

Mayo Clinic

Clinical Transplantation | May 7, 2025 | Volume: 39 | Issue: 5 | Pages: No page available

10.1111/ctr.70180 | PMID 40329150 Get It

ABSTRACTThe incidence of ischemic cholangiopathy (IC) is expected to remain significant due to rising rates of transplants performed with livers donated after circulatory death (DCD), despite the use of machine perfusion. Absent established pharmacologic interventions against this progressive etiology of allograft dysfunction and failure, we describe the use of fenofibrate—a cheap and widely‐accessible peroxisome proliferator‐activated receptor agonist that downregulates bile acid production—to impede IC progression in 15 DCD liver recipients who were not responding to reactive, standard‐of‐care management. All patients were undergoing serial endoscopic retrograde cholangiopathy (ERC) to maintain biliary patency but demonstrated progressive cholestasis, with serum alkaline phosphatase (ALP) rising 70.3% over the 90 days preceding fenofibrate. Cholestasis improved in all patients after fenofibrate initiation, with a 63.9% reduction in mean ALP at 90 days, maintained at 270 days (p = 0.02) and 360 days (p = 0.06). ALP improvement was associated with reduced ERC frequency during and after fenofibrate treatment, and this improvement was independent of concurrent ERC or ursodeoxycholic acid use during fenofibrate treatment. In patients who stopped treatment, ALP increased. No fenofibrate‐associated adverse events were seen. These preliminary data support the further study of agents that downregulate bile acid production as a means of impeding IC in DCD livers.